The oncology market size is poised to grow by $ 470.61 billion by 2032 from $ 203.42 Billion in 2022, exhibiting a CAGR of 8.8% during the forecast period 2023-2032.
Key Takeaway:
- The cancer diagnostic segment has accounted 46.8% of the total market share in 2021.
- Hospital segment is growing at a CAGR of 10.9% from 2023 to 2032.
- Breast cancer market was valued at USD 57.23 billion in 2021.
- North America region has reached 46.2% of total market share in 2021.
The main objective of this report is to define, describe, and forecast the global market by types, application, manufacturers, and regions. The report provides detailed information about the major factors (drivers, restraints, opportunities, and industry-specific challenges) influencing the growth of the market. The report aims to strategically analyze the micro markets with respect to individual growth trends, prospects, and contributions to the global market. The report also attempts to forecast the market size of the 5 main regions: North America, Europe, Asia Pacific (APAC), Middle East and Africa (MEA), and Latin America. It strategically profiles the key market players and comprehensively analyzes their core competencies. It also tracks and analyzes competitive developments, such as joint ventures, mergers and acquisitions, new developments, and Research and Development (R&D) activities, in market.
Get a Sample: https://www.precedenceresearch.com/sample/1467
COVID-19 Impact
Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the electric vehicle fuel cell market in 2020.
COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.
The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.
Major companies operating in this area
- Aegerion Pharmaceuticals Inc.
- Abbvie Inc.
- Ability Pharma
- Acadia Pharmaceuticals Inc.
- Amgen Inc.
- Takeda Oncology
- Aslan Pharmaceuticals Ltd.
- Aspen Pharmacare Holdings Limited.
- Astrazeneca
- Athenex, Inc.
Market Segmentation
By Cancer Diagnostics & Treatment
- Cancer Diagnostics
- Biopsy
- Imaging
- Immunohistochemistry
- Tumor Biomarkers Test
- In Situ Hybridization
- Liquid Biopsy
- Cancer Treatment
- Targeted Therapy
- Chemotherapy
- Hormonal Therapy
- Immunotherapy
- Others
By Indication
- Lungs Cancer
- Colorectal Cancer
- Breast Cancer
- Liver Cancer
- Bladder Cancer
- Head & Neck Cancer
- Prostate Cancer
- Others
By End-use
- Hospitals
- Diagnostic laboratories
- Diagnostic imaging centers
- Academia
- Specialty clinics
- Others
By Geography
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- France
- Asia Pacific
- China
- India
- Japan
- South Korea
- MEA
- Rest of the World
Major highlights of Report:
- Figures related to sales volume, market remuneration, and segmental shares
- Featuring market dynamics
- Growth prospects and expansion graph
- PROCON study of direct & indirect sales channels
- Profiles of prominent traders, dealer, and distributors in the industry
Geographical landscape: North America, Europe, Asia-Pacific, South America, Middle East and Africa
- Industry forecasts based on region and at country level
- Data about sales volume recorded, industry share held, and profit margins amassed
- Overall remuneration and estimated growth rate for each regional market
Major Key Points Covered in Report:
Executive Summary: It includes key trends of the electric vehicle fuel cell market related to products, applications, and other crucial factors. It also provides analysis of the competitive landscape and CAGR and market size of the electric vehicle fuel cell market based on production and revenue.
Production and Consumption by Region: It covers all regional markets to which the research study relates. Prices and key players in addition to production and consumption in each regional market are discussed.
Key Players: Here, the report throws light on financial ratios, pricing structure, production cost, gross profit, sales volume, revenue, and gross margin of leading and prominent companies competing in the Electric vehicle fuel cell market.
Market Segments: This part of the report discusses product, application and other segments of the electric vehicle fuel cell market based on market share, CAGR, market size, and various other factors.
Research Methodology: This section discusses the research methodology and approach used to prepare the report. It covers data triangulation, market breakdown, market size estimation, and research design and/or programs.
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Oncology Market
5.1. COVID-19 Landscape: Oncology Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Oncology Market, By Indication
8.1. Oncology Market, by Indication Type, 2021-2030
8.1.1. Lungs Cancer
8.1.1.1. Market Revenue and Forecast (2019-2030)
8.1.2. Colorectal Cancer
8.1.2.1. Market Revenue and Forecast (2019-2030)
8.1.3. Breast Cancer
8.1.3.1. Market Revenue and Forecast (2019-2030)
8.1.4. Liver Cancer
8.1.4.1. Market Revenue and Forecast (2019-2030)
8.1.5. Bladder Cancer
8.1.5.1. Market Revenue and Forecast (2019-2030)
8.1.6. Head & Neck Cancer
8.1.6.1. Market Revenue and Forecast (2019-2030)
8.1.7. Prostate Cancer
8.1.7.1. Market Revenue and Forecast (2019-2030)
8.1.8. Others
8.1.8.1. Market Revenue and Forecast (2019-2030)
Chapter 9. Global Oncology Market, By Cancer Diagnostics & Treatment
9.1. Oncology Market, by Cancer Diagnostics & Treatment, 2021-2030
9.1.1. Cancer Diagnostics (Biopsy, Imaging, Immunohistochemistry, Tumor Biomarkers Test, In Situ Hybridization, Liquid Biopsy)
9.1.1.1. Market Revenue and Forecast (2019-2030)
9.1.2. Cancer Treatment (Targeted Therapy, Chemotherapy, Hormonal Therapy, Immunotherapy, Others)
9.1.2.1. Market Revenue and Forecast (2019-2030)
Chapter 10. Global Oncology Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Indication (2019-2030)
10.1.2. Market Revenue and Forecast, by Cancer Diagnostics & Treatment (2019-2030)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Indication (2019-2030)
10.1.3.2. Market Revenue and Forecast, by Cancer Diagnostics & Treatment (2019-2030)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Indication (2019-2030)
10.1.4.2. Market Revenue and Forecast, by Cancer Diagnostics & Treatment (2019-2030)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Indication (2019-2030)
10.2.2. Market Revenue and Forecast, by Cancer Diagnostics & Treatment (2019-2030)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Indication (2019-2030)
10.2.3.2. Market Revenue and Forecast, by Cancer Diagnostics & Treatment (2019-2030)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Indication (2019-2030)
10.2.4.2. Market Revenue and Forecast, by Cancer Diagnostics & Treatment (2019-2030)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Indication (2019-2030)
10.2.5.2. Market Revenue and Forecast, by Cancer Diagnostics & Treatment (2019-2030)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Indication (2019-2030)
10.2.6.2. Market Revenue and Forecast, by Cancer Diagnostics & Treatment (2019-2030)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Indication (2019-2030)
10.3.2. Market Revenue and Forecast, by Cancer Diagnostics & Treatment (2019-2030)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Indication (2019-2030)
10.3.3.2. Market Revenue and Forecast, by Cancer Diagnostics & Treatment (2019-2030)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Indication (2019-2030)
10.3.4.2. Market Revenue and Forecast, by Cancer Diagnostics & Treatment (2019-2030)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Indication (2019-2030)
10.3.5.2. Market Revenue and Forecast, by Cancer Diagnostics & Treatment (2019-2030)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Indication (2019-2030)
10.3.6.2. Market Revenue and Forecast, by Cancer Diagnostics & Treatment (2019-2030)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Indication (2019-2030)
10.4.2. Market Revenue and Forecast, by Cancer Diagnostics & Treatment (2019-2030)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Indication (2019-2030)
10.4.3.2. Market Revenue and Forecast, by Cancer Diagnostics & Treatment (2019-2030)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Indication (2019-2030)
10.4.4.2. Market Revenue and Forecast, by Cancer Diagnostics & Treatment (2019-2030)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Indication (2019-2030)
10.4.5.2. Market Revenue and Forecast, by Cancer Diagnostics & Treatment (2019-2030)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Indication (2019-2030)
10.4.6.2. Market Revenue and Forecast, by Cancer Diagnostics & Treatment (2019-2030)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Indication (2019-2030)
10.5.2. Market Revenue and Forecast, by Cancer Diagnostics & Treatment (2019-2030)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Indication (2019-2030)
10.5.3.2. Market Revenue and Forecast, by Cancer Diagnostics & Treatment (2019-2030)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Indication (2019-2030)
10.5.4.2. Market Revenue and Forecast, by Cancer Diagnostics & Treatment (2019-2030)
Chapter 11. Company Profiles
11.1. Aegerion Pharmaceuticals Inc.
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Abbvie Inc.
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Ability Pharma
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Acadia Pharmaceuticals Inc.
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Amgen Inc.
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Takeda Oncology
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Aslan Pharmaceuticals Ltd.
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Aspen Pharmacare Holdings Limited.
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Astrazeneca
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Athenex, Inc.
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Web: https://www.precedenceresearch.com
Blog: https://www.pharma-geek.com
0 Comments